Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
- DOI
- 10.1016/j.annonc.2021.01.070
- Published
- 2021 May
- Container
- Annals of oncology : official journal of the European Society for Medical Oncology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.annonc.2021.01.070,
title = {Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.},
author = {Tempero M and Oh DY and Tabernero J and Reni M and Van Cutsem E and Hendifar A and Waldschmidt DT and Starling N and Bachet JB and Chang HM and Maurel J and Garcia-Carbonero R and Lonardi S and Coussens LM and Fong L and Tsao LC and Cole G Jr and James D and Macarulla T},
year = {2021},
journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
doi = {10.1016/j.annonc.2021.01.070},
url = {https://doi.org/10.1016/j.annonc.2021.01.070}
}RIS
TY - JOUR TI - Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. AU - Tempero M AU - Oh DY AU - Tabernero J AU - Reni M AU - Van Cutsem E AU - Hendifar A AU - Waldschmidt DT AU - Starling N AU - Bachet JB AU - Chang HM AU - Maurel J AU - Garcia-Carbonero R AU - Lonardi S AU - Coussens LM AU - Fong L AU - Tsao LC AU - Cole G Jr AU - James D AU - Macarulla T PY - 2021 JO - Annals of oncology : official journal of the European Society for Medical Oncology DO - 10.1016/j.annonc.2021.01.070 UR - https://doi.org/10.1016/j.annonc.2021.01.070 ER -
APA
M, T., DY, O., J, T., M, R., E, V. C., A, H., DT, W., N, S., JB, B., HM, C., J, M., R, G., S, L., LM, C., L, F., LC, T., Jr, C. G., D, J., & T, M. (2021). Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2021.01.070
Source records
- pubmed · retrieved 2026-09-26T21:03:00.781Z